Navigation Links
China-Biotics, Inc. Applies for Four Patents on Probiotic Formulations
Date:7/31/2009

SHANGHAI, July 31 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics", "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced it has submitted applications for four patents to the State Intellectual Property Office of the People's Republic of China.

These applications are patents for a protein powder formulation; home yogurt fermentation, a retail powder that enables customers to make yogurt at home; a yogurt powder; and a health-enhancing yogurt. All of these applications are for probiotics-based products. Currently, the Intellectual Property Office is conducting an official review of these applications. It takes about two years to obtain patent certificates under normal circumstances.

"These four new formulations are the result of sustained product development by our highly skilled staff of more than 30 researchers with advanced degrees and our extensive relationships with academic institutions," said Mr. Jinan Song, Chairman and Chief Executive Officer of China-Biotics.

The Company also announced that Mr. Zhenjia Bian and Mr. Chengdong Yi, senior officials from the State Food and Drug Administration, visited the Company recently. The visit coincided with China's new umbrella food safety law, which sets more stringent standards for food production throughout China. The officials praised the Company's significant achievements in probiotics applications during the past decade and encouraged management to continue its business expansion efforts.

About China-Biotics, Inc.

China-Biotics, Inc. ("China-Biotics," "the Company"), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements. Through its wholly owned subsidiary, Shanghai Shining Biotechnology Co., Ltd., the Company has operations in Shanghai. Its proprietary product portfolio contains live microbial nutritional supplements under the "Shining" brand. Currently, the products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang. China-Biotics plans to launch 300 Shining brand retail outlets in major cities in China. Currently, China-Biotics is strategically expanding its production capacity of probiotics to meet growing demand in the bulk additive market. For more information, please visit http://www.chn-biotics.com .

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors include, but are not limited to, the Company's ability to obtain the patents applied for, market existing and new products and changes from anticipated levels of sales, future national or regional economic and competitive conditions, market acceptance of its retail store concept, changes in relationships with customers, dependence on its flagship product profits and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    For more information, please contact:

    CCG Investor Relations
     Crocker Coulson, President
     Phone: +1-646-213-1915 (New York)
     Email: crocker.coulson@ccgir.com
     Web:  http://www.ccgirasia.com

'/>"/>
SOURCE China-Biotics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results
2. China-Biotics, Inc. Announces Conference Call to Discuss Fourth Quarter and Full Year 2009 Financial Results
3. China-Biotics, Inc. to Join Russell 3000 Index
4. China-Biotics, Inc. to Attend Digestive Disease Week 2009
5. China-Biotics, Inc. to Present at CCG Investor Relations China Rising Conference
6. China-Biotics, Inc. Supplies Probiotics as Additive for Poultry Feed
7. China-Biotics, Inc. Appoints New Chief Financial Officer
8. China-Biotics, Inc. to Present at Roth Capital Partners 21st Annual OC Growth Stock Conference
9. China-Biotics, Inc. Receives Manufacturing Certificate for New Products
10. China-Biotics, Inc. Reports Second Quarter 2009 Financial Results
11. China-Biotics, Inc. Retains KPMG for the Implementation of Sarbanes-Oxley Act Section 404
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):